According to Michael McMullen, CEO, president, and director of Agilent, the company’s pathology business led to growth for the Diagnostics and Genomics Group. This includes the introduction of Agilent’s end-to-end digital pathology workflow solution, which is made up of offerings from Proscia, Visiopharm, Hamamatsu, and Agilent, at USCAP.
Featured Story:
Latest Articles
October 1, 2024